Treatment of patients with hepatitis C virus genotype 3: Where are we now?

Watch a video presentation of this article

[1]  F. Carrat,et al.  LP05 : Daclatasvir plus sofosbuvir with or without ribavirin in patients with HCV genotype 3 infection: Interim analysis of a french multicenter compassionate use program , 2015 .

[2]  C. Cooper,et al.  LO5 : Sofosbuvir + peginterferon/ribavirin for 12 weeks vs sofosbuvir + ribavirin for 16 or 24 weeks in genotype 3 HCV infected patients and treatment-experienced cirrhotic patients with genotype 2 HCV: The boson study , 2015 .

[3]  A. Howe,et al.  O006 : C-swift: grazoprevir/elbasvir + sofosbuvir in cirrhotic and noncirrhotic, treatment-naive patients with hepatitis C virus genotype 1 infection, for durations of 4, 6 or 8 weeks and genotype 3 infection for durations of 8 or 12 weeks , 2015 .

[4]  P. Pang,et al.  O005 : Retreatment of patients who failed 8 or 12 weeks of ledipasvir/sofosbuvir-based regimens with ledipasvir/sofosbuvir for 24 weeks , 2015 .

[5]  P. Thuluvath,et al.  All-Oral 12-Week Treatment With Daclatasvir Plus Sofosbuvir in Patients With Hepatitis C Virus Genotype 3 Infection: ALLY-3 Phase III Study , 2015, Hepatology.

[6]  H. El‐Serag,et al.  HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCV , 2014, Hepatology.

[7]  C. Stedman,et al.  O6 SOFOSBUVIR/LEDIPASVIR FIXED DOSE COMBINATION IS SAFE AND EFFECTIVE IN DIFFICULT-TO-TREAT POPULATIONS INCLUDING GENOTYPE-3 PATIENTS, DECOMPENSATED GENOTYPE-1 PATIENTS, AND GENOTYPE-1 PATIENTS WITH PRIOR SOFOSBUVIR TREATMENT EXPERIENCE , 2014 .

[8]  M. Mondelli,et al.  Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysis. , 2009, Journal of hepatology.